Taiwan National Health Insurance Administration of the Ministry of Health and Welfare approves Vemlidy (tenofovir alafenamide) for reimbursement


29 April 2019 - Vemlidy has shown improved renal and bone safety profiles compared to TDF making it an important first-line treatment option for chronic hepatitis B.

Gilead Sciences today announced that with effect from 1 May 2019, Vemlidy (tenofovir alafenamide, TAF) 25 mg, a once-daily treatment for chronic hepatitis B in adults with compensated liver disease will be made available to patients via the National Health Insurance (NHI) scheme.

Vemlidy's approval is supported by data from two international Phase 3 studies (Studies 108 and 110) among 1,632 treatment-naive and treatment-experienced adult patients with HBeAg-negative and HBeAg-positive HBV disease (including 120 treated in Taiwan). In an integrated analysis of both studies, patients receiving Vemlidy demonstrated improvements in certain bone and renal laboratory parameters compared to those treated with Viread.

Read Gilead press release 

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Funding , Taiwan